Drug intelligence / Profile preview

[F-18]FDG + [F-18]DPA-714-University of Alabama at Birmingham

Development stage: Unknown
Lead developer: University of Alabama at Birmingham
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[F-18]FDG + [F-18]DPA-714-University of Alabama at Birmingham refers to a dual-tracer positron emission tomography (PET) imaging protocol being evaluated by the University of Alabama at Birmingham for patients with idiopathic pulmonary fibrosis (IPF). The strategy involves the sequential administration of two distinct radiopharmaceuticals: fluorine-18 fluorodeoxyglucose ([F-18]FDG) and [F-18]DPA-714. [F-18]FDG is a glucose analog that accumulates in metabolically active cells, such as activated fibroblasts and inflammatory cells, following phosphorylation by hexokinase. [F-18]DPA-714 is a second-generation radioligand that binds with high affinity to the translocator protein (TSPO), which is overexpressed on the outer mitochondrial membrane of activated macrophages and fibroblasts. By utilizing both probes, researchers aim to characterize the heterogeneity of IPF by simultaneously assessing metabolic activity and macrophage-driven inflammation, potentially improving patient stratification and monitoring of treatment response.

Other names: fluorodeoxyglucose F 18 + [F-18]DPA-71418F-FDG + 18F-DPA-714

Targets

GCK (Glucokinase)TSPO (Translocator Protein (18 kDa))GLUT1 (Glucose transporter 1)

Beyond the preview

Go deeper on [F-18]FDG + [F-18]DPA-714-University of Alabama at Birmingham.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [F-18]FDG + [F-18]DPA-714-University of Alabama at Birmingham.

Explore the full profile